Haematology

The Department of Haematology is responsible for treatment of all haematological disorders in adults according to internationally accepted guidelines and standards. The department is a centre of expertise for the treatment of blood diseases in Denmark.
The Department of Haematology charter is to provide optimum patient care and as widely as possible, add to the knowledge of the aetiology and pathogenesis of the blood disorders that are treated within the clinic. Also to develop more effective treatments and to build upon the existing understanding of haematological disorders.

Senior physician Lars Kjeldsen has overall responsibility for the department along with senior nurse Pernille Welinder.
The haematological disorders treated include amongst others

• non malignant blood diseases such as, anaemia and haemostatic disorders
• malignant lymphoma
• multiple myeloma
• acute leukaemias as well as chronic lympho- and myeloproliferative disorders.

The department provides bone marrow transplantations both with the patients own stem cells or with bone marrow from related and unrelated donors.
 

The department is organized into 3 integrated units
which each comprise out-patients, day-care and ward units. Each unit is led by a management group comprising a specialist doctor, a department nurse and a secretary.

Unit 1: Lymphoma and multiple myeloma
4032/4033/4034 (ward and outpatients) responsible for treatment of malignant lymphoma and multiple myeloma.

Unit 1 management team:
Senior physician: John Myhre
Department nurse: Birgith Skovsgaard
Secretary: Vacant

Unit 2: Allogeneic bone marrow transplantation
4041/4042/4043 and 4044 (ward and outpatients) responsible for the treatment of allogeneic and autologous bone marrow transplantation.

Unit 2 management team:
Senior physician: Doris Hovgaard
Department nurse: Laila von der Maase
Secretary: Vivi Ljungberg

Unit 3: Leukaemia, coagulation and benign blood disorders
5052/4054 (ward and outpatients) responsible for the treatment of acute leukaemia, chronic myeloproliferative disorders, chronic lymphatic leukaemia along with non-malignant haematological disorders.

Unit 3 management team:
Senior physician: Peter Kampmann
Department nurse: Tina Lanther 
Secretary: Rikke Ulrik


The following haematologists have responsibility
for the treatment, treatment programs and consultancy for the haematological disorders.

• Malignant Lymphoma: Senior physician John Myhre and Lena Specht
• Myeloma and other chronic lymphoproliferative diseases excluding CLL and malignant lymphoma: Senior physician Peter Gimsing
• Allogenic bone marrow transplantation: Senior physician: Henrik Sengeløv
• Mini Transplantation: Senior physician Lars Vindeløv
• Autologous bone marrow transplantation: Senior physician Christian Geisler
• Acute Leukaemia: Senior physician Ove Juul Nielsen
• Chronic myeloproliferative disorders: Senior physician Ole Weis Bjerrum
• Myelodysplastic syndrom, aplastic anaemia, thrombocytopenia, benign haematology: Senior physician Lars Kjeldsen
• Haemostatic disorders: Senior physician Jørn Dalsgaard-Nielsen
  

Research and Development
The clinic's research effort is focussed in the areas of:

• Quantifying of allergic reactions, immune system function, graft-versus-host sickness, graft-versus-leukaemia effect and minimal residual sickness.
• To undertake experimental research in autologous stem cell transplantation among these specifically, minimal residual disease and the function of cell-cycle aberrations with respect to the success of high dose therapy.
• To investigate cell and the molecular biology of CD5+B-cell malignancies. (B-cell chronic lymphatic leukaemia (CLL) and mantle cell lymphoma(MCL), especially the molecular regulation of cell cycles and apoptosis.
• Neutrophile granulocytic cell biology, focussing on the functional characteristics of 3 newly discovered proteins, hCAP-18, NGAL and Grancalcin.
• Regulation of gene transcription during myelopoiesis in normal and malignant cells.
• The clinical effect of high dose treatment and autologous stem cell transplantation in relation to leukaemia, malignant lymphoma and myeloma.
• Flow cytometric quantifying of activated thrombocytes in relation to chronic myeloproliferative diseases.Flow cytometric quantifying of circulating thrombocytes-leukocyte aggregations in relation to chronic myeloproliferative diseases. Quantifying of fribrosis and coagulation parameters in the same patient group.